Clinical trial

Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

NCT04591015

Study summary

ClinicalTrials.gov

Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BEHAVIORAL · Unmapped registry intervention Hospital: DD-CA Find medicine records · Find other trials using this name

BEHAVIORAL · Unmapped registry intervention Hospital: Usual Care (UC) Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-02-01

PhaseNA

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Covid19unresolved

Interventions

Hospital: DD-CABEHAVIORAL

Hospital: Usual Care (UC)BEHAVIORAL

Sponsors & collaborators

Scripps Whittier Diabetes Institutelead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Mapped research locations

Chula VistaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04591015 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.